Yajin Chen
Overview
Explore the profile of Yajin Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chen Y, Du C, Shen S, Zhang W, Shan Y, Lyu A, et al.
Clin Cancer Res
. 2024 Apr;
30(14):2937-2944.
PMID: 38687583
Purpose: This phase II, multicenter, prospective, single-arm study aimed to evaluate the efficacy and safety of toripalimab plus bevacizumab for treating advanced hepatocellular carcinoma (HCC). Patients And Methods: Treatment-naïve patients...
12.
Tang C, Zhuang H, Wang W, Wang Q, Ma X, Wang B, et al.
Cell Death Dis
. 2024 Mar;
15(3):191.
PMID: 38443362
Circular RNAs (circRNAs) have been implicated in tumorigenesis and progression of various cancers. However, the underlying mechanisms of circRNAs in hepatocellular carcinoma (HCC) have not been fully elucidated. Herein, a...
13.
Zhuang H, Tang C, Lin H, Zhang Z, Chen X, Wang W, et al.
Cell Oncol (Dordr)
. 2024 Feb;
47(4):1205-1220.
PMID: 38315287
Purpose: Although mRNA vaccines have shown certain clinical benefits in multiple malignancies, their therapeutic efficacies against hepatocellular carcinoma (HCC) remains uncertain. This study focused on establishing a novel risk score...
14.
Qin S, Chan S, Gu S, Bai Y, Ren Z, Lin X, et al.
Lancet
. 2023 Jul;
402(10408):1133-1146.
PMID: 37499670
Background: Immunotherapy with immune checkpoint inhibitors combined with an anti-angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus anti-angiogenic therapy alone in advanced solid tumours, but not...
15.
Ren Z, Ducreux M, Abou-Alfa G, Merle P, Fang W, Edeline J, et al.
Liver Cancer
. 2023 Mar;
12(1):72-84.
PMID: 36872927
Introduction: Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the...
16.
Cao J, Chen Y
Hepatobiliary Surg Nutr
. 2023 Mar;
12(1):84-87.
PMID: 36860240
No abstract available.
17.
Tan W, Zhang K, Chen X, Yang L, Zhu S, Wei Y, et al.
J Adv Res
. 2023 Feb;
44:173-183.
PMID: 36725188
Introduction: Lenvatinib has recently become available as the first-line therapy for advanced hepatocellular carcinoma (HCC), but its molecular mechanism in HCC remains largely unknown. Objectives: The current study aims to...
18.
Wang Q, Wang B, Ma X, Zhuang H, Xie Z, Tang C, et al.
J Hepatocell Carcinoma
. 2023 Jan;
10:1-16.
PMID: 36647389
Purpose: Ferroptosis has been reported to regulate multiple biological behaviors. However, the prognostic and oncologic values of ferroptosis-related genes (FRGs) have not been comprehensively elucidated in hepatocellular carcinoma (HCC). Here,...
19.
Ding Z, Wu H, Zeng Y, Kuang M, Yang W, Meng Z, et al.
Hepatol Int
. 2022 Oct;
17(1):180-189.
PMID: 36258065
Purpose: Probing efficacy and safety of lusutrombopag in Chinese chronic liver disease (CLD) and severe thrombocytopenia (PLT < 50 × 10/L) patients undergoing elective invasive procedures. Methods: In this double-blind,...
20.
Zhuang H, Chen B, Tang C, Chen X, Tan W, Yang L, et al.
Front Oncol
. 2022 Jun;
12:871771.
PMID: 35646684
Background: Smith-like (LSM) family members play critical roles in multiple oncologic processes in several types of malignancies. The study on LSM family members of HCC might provide new insights into...